Endo License and Development Agreement - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended					1 Months Ended	3 Months Ended
	Mar. 31, 2014 Milestone	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Jan. 23, 2014	May 31, 2012	Jan. 17, 2012	May 31, 2012 Endo License and Development Agreement [Member]	Mar. 31, 2014 Endo License and Development Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]
Non-refundable payment received							$ 30,000,000
Potential milestone payments	95,000,000
Number of potential milestone payments	6
Potential milestone payments on intellectual property rights	35,000,000
Potential milestone payments on issuance of patent	15,000,000					15,000,000
Potential milestone payment receivable clinical development	20,000,000
Potential milestone payment receivable regulatory events	40,000,000								50,000,000
Payment receivable on achievement of potential sales milestones	55,000,000
Number of potential sales milestones	4
Recognized up-front payment allocated to the license	15,600,000
Recognized up-front payment to clinical trial material and development services	14,400,000
Upfront payment	0
Aggregate milestones and services revenue recognized	11,283,833	1,621,977						15,000,000
Estimated amount recognized against clinical services deliverable	1,200,000		6,300,000	5,200,000
Deferred revenue income of the research and development activities	1,700,000								8,500,000
Term of Endo Agreement	10 years
Extended patent on drug delivery technology	2020 to 2027
Total rate of reimbursable contractor costs borne	50.00%								50.00%
Reimbursement rate of costs by Endo to the company as per agreement									100.00%
Percentage of credit against potential future milestone									50.00%
Deffered revenue recognized during the period	1,200,000
Milestone payment regarding licensing agreement					$ 10,000,000